Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
J Clin Invest. 1995 Jun;95(6):2611-9. doi: 10.1172/JCI117963.
The murine monoclonal antibody mAb-1H11 raised against malondialdehyde (MDA)-modified LDL, was used to detect cross-reacting material in human atheromatous tissue and in plasma. MDA-modified LDL levels in plasma were 0.19 +/- 0.02 mg/dl (mean +/- SEM) in 44 control subjects, 0.24 +/- 0.02 mg/dl in 15 patients with chronic stable angina pectoris (P = NS vs LDL cholesterol matched controls), 1.4 +/- 0.1 mg/dl in 60 patients with acute myocardial infarction (P < 0.001 vs controls), and 0.86 +/- 0.11 mg/dl in 22 patients with carotid atherosclerosis (P < 0.001 vs controls). Modified LDL, isolated from pooled LDL of 10 patients, showed a higher electrophoretic mobility on agarose gels, a higher content of thiobarbituric acid reactive substances, and a higher cholesterol/protein ratio than native LDL and had a similar reactivity (antigen/protein ratio) in the assay as the in vitro MDA-modified LDL used for calibration. Its apo B-100 moiety was not fragmented. Uptake of this modified LDL by macrophages resulted in foam cell generation. In conclusion, elevated plasma levels of atherogenic MDA-modified LDL may be a marker for unstable atherosclerotic cardiovascular disease.
针对丙二醛（MDA）修饰的低密度脂蛋白（LDL）产生的鼠单克隆抗体mAb-1H11，用于检测人动脉粥样硬化组织和血浆中的交叉反应物质。44名对照受试者血浆中MDA修饰的LDL水平为0.19±0.02mg/dl（平均值±标准误），15名慢性稳定型心绞痛患者为0.24±0.02mg/dl（与LDL胆固醇匹配的对照组相比，P=无显著性差异），60名急性心肌梗死患者为1.4±0.1mg/dl（与对照组相比，P<0.001），22名颈动脉粥样硬化患者为0.86±0.11mg/dl（与对照组相比，P<0.001）。从10名患者的混合LDL中分离出的修饰LDL，在琼脂糖凝胶上显示出更高的电泳迁移率，硫代巴比妥酸反应性物质含量更高，胆固醇/蛋白质比率高于天然LDL，并且在测定中的反应性（抗原/蛋白质比率）与用于校准的体外MDA修饰的LDL相似。其载脂蛋白B-100部分未断裂。巨噬细胞摄取这种修饰的LDL导致泡沫细胞生成。总之，致动脉粥样硬化的MDA修饰的LDL血浆水平升高可能是不稳定动脉粥样硬化性心血管疾病的一个标志物。
